HCPCS Level II code J2778 denotes an injection of ranibizumab, 0.1 mg, an anti-VEGF medication administered via intravitreal injection to manage retinal diseases that threaten vision. Nationally, accurate coding for this drug matters for care continuity, billing consistency, and proper tracking of high-cost ophthalmic therapies.

Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the code’s clinical role, common sites of service, and the payer landscape relevant to coverage and claim adjudication. The publication summarizes benchmarking and reimbursement context where available, outlines common billing considerations tied to intravitreal injections, and highlights recent policy developments and coding guidance that affect access and prior authorization practices.

This summary is intended for clinicians, coding professionals, and revenue cycle staff seeking a national overview of HCPCS Level II code J2778, its clinical application, and the payer considerations that influence billing and coverage for ranibizumab intravitreal therapy.